enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 60,300 shares, a decrease of 31.9% from the February 13th total of 88,500 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 131,100 shares, the days-to-cover ratio is currently 0.5 days.
enGene Stock Up 0.9 %
Shares of NASDAQ ENGN opened at $5.40 on Friday. enGene has a one year low of $4.42 and a one year high of $18.40. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. The firm’s 50 day simple moving average is $6.51 and its two-hundred day simple moving average is $7.11. The stock has a market capitalization of $275.28 million, a P/E ratio of -9.31 and a beta of -0.61.
enGene (NASDAQ:ENGN – Get Free Report) last issued its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. As a group, analysts expect that enGene will post -1.56 EPS for the current fiscal year.
Analysts Set New Price Targets
Get Our Latest Report on enGene
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Fcpm Iii Services B.V. grew its position in enGene by 11.0% during the fourth quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company’s stock valued at $64,057,000 after acquiring an additional 954,610 shares during the last quarter. VR Adviser LLC grew its holdings in shares of enGene by 41.5% in the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock worth $33,559,000 after purchasing an additional 1,480,573 shares during the last quarter. Deep Track Capital LP grew its holdings in shares of enGene by 74.8% in the fourth quarter. Deep Track Capital LP now owns 4,557,575 shares of the company’s stock worth $30,308,000 after purchasing an additional 1,949,942 shares during the last quarter. Blue Owl Capital Holdings LP grew its holdings in shares of enGene by 3.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock worth $21,014,000 after purchasing an additional 101,006 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of enGene by 84.7% in the fourth quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company’s stock worth $8,145,000 after purchasing an additional 561,797 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Further Reading
- Five stocks we like better than enGene
- Manufacturing Stocks Investing
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Options Trading – Understanding Strike Price
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.